Q2 Earnings Forecast for Quanterix Issued By Leerink Partnrs

Quanterix Corporation (NASDAQ:QTRX) – Leerink Partnrs dropped their Q2 2026 EPS estimates for Quanterix in a report released on Monday, October 13th. Leerink Partnrs analyst P. Souda now forecasts that the company will post earnings of ($0.20) per share for the quarter, down from their previous forecast of ($0.17). The consensus estimate for Quanterix’s current full-year earnings is ($0.98) per share. Leerink Partnrs also issued estimates for Quanterix’s Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.67) EPS and FY2027 earnings at ($0.43) EPS.

A number of other brokerages also recently issued reports on QTRX. Canaccord Genuity Group reaffirmed a “hold” rating and issued a $5.00 price objective (down from $12.00) on shares of Quanterix in a research report on Monday, August 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Quanterix in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $11.75.

Quanterix Stock Performance

Shares of QTRX stock opened at $5.95 on Thursday. Quanterix has a 52-week low of $4.05 and a 52-week high of $15.67. The company has a 50-day simple moving average of $5.09 and a two-hundred day simple moving average of $5.47. The company has a market capitalization of $276.50 million, a price-to-earnings ratio of -3.27 and a beta of 1.07.

Quanterix (NASDAQ:QTRX) last posted its earnings results on Thursday, August 7th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.06). Quanterix had a negative return on equity of 18.41% and a negative net margin of 56.04%.The business had revenue of $24.48 million for the quarter, compared to the consensus estimate of $29.73 million. Quanterix has set its FY 2025 guidance at EPS.

Institutional Trading of Quanterix

Institutional investors have recently modified their holdings of the business. State of Wyoming bought a new position in Quanterix in the 1st quarter valued at $47,000. Quantbot Technologies LP boosted its holdings in Quanterix by 245.9% in the 1st quarter. Quantbot Technologies LP now owns 11,272 shares of the company’s stock valued at $73,000 after purchasing an additional 8,013 shares during the period. Aaron Wealth Advisors LLC bought a new position in Quanterix in the 1st quarter valued at $79,000. HUB Investment Partners LLC bought a new position in Quanterix in the 2nd quarter valued at $81,000. Finally, Brevan Howard Capital Management LP bought a new position in Quanterix in the 2nd quarter valued at $96,000. 86.48% of the stock is currently owned by hedge funds and other institutional investors.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.